All In Biotech

NDA 017031 · Laboratoire Hra

Opill

Norgestrel · Oral

Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1973

Oct 23, 1973

Approved uses

2

Original approval plus efficacy supplements

Registered trials

174

43 Phase 3, 9 recruiting

FAERS reports

1,356

302 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 6, 2026.

Use To prevent pregnancy

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • OPILL · NORGESTREL 0.075MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Norgestrel" as an intervention, any sponsor and status, largest first.

All 174 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • heavy menstrual bleeding245
  • pregnancy on oral contraceptive206
  • intermenstrual bleeding182
  • polymenorrhoea155
  • product dose omission issue79
  • nausea77
  • adverse drug reaction68
  • headache66
  • weight increased63
  • acne53
  • dysmenorrhoea52
  • menstruation irregular51

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20051
20081
20104
20113
20122
20135
20142
20156
20164
20171
20182
20192
20204
20212
20224
20234
2024349
2025937
202621

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 153 on PubMed

Sponsor: Laboratoire Hra

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.